Please also watch the other modules from this session: IBD Immunology and Emerging Therapies, Small Molecules (JAKi/S1P agonists), IL-12/23 and IL-23 Receptor Antagonists, and the IBD Immunology and What is New in Anti -TNFs and Anti-Integrins?
Crohn's Colitis Professional
Current Therapies and Those in the Pipeline Q & A
2
- Guest: Joel Pekow, MD, MPH
- Guest: Sara Horst, MD, MPH
- Guest: Parambir S. Dulai, MD
- Guest: Kara DeFelice, MD
- Guest: Matthew Ciorba, MD
This is a module of the session titled Current Therapies and Those in the Pipeline originally presented during the Crohn’s & Colitis Foundation Central Regional Professional Education Conference at Washington University: Cutting Edge Approaches to IBD Management on Sept 24, 2022, and supported in part by unrestricted educational grants from Boehringer Ingelheim, Bristol Myers Squibb, Ferring Pharmaceuticals, Janssen, and Pfizer, Inc.
Accreditation Information:
You will receive credit for watching the other modules of this session but the Q & A portion is not accredited.
Learning Objectives
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Discuss studies to identify next generation IBD therapies
- Analyze the literature of updates in use of anti-tnf and anti-integrin therapies in IBD
- Describe the mechanism and rationale behind the development of targeted IL 12/23 and IL 23 inhibitors
- Evaluate current efficacy and safety data for approved IL 23 inhibitors for the management of IBD and Crohn's disease
- Identify the currently available janus kinase (JAK) inhibitors and S1P modulator for the treatment of moderate to severe ulcerative colitis
- Implement the safety monitoring required prior to and during treatment with JAK inhibitors and S1P modulators
Facebook Comments